8-K ·Filed Apr 30, 2026

INDV

Indivior Pharmaceuticals, Inc.
BULLISH
Impact 8/10
Horizonweeks Processed5mo ago SEC0001193125-26-193925
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q1 beat and raised guidance confirm accelerating SUBLOCADE momentum and operating leverage. With $275M remaining on the buyback and a strengthened balance sheet, the stock should re-rate higher. Monitor the Q2 dispense unit growth trajectory and any business development announcements as the company targets Phase III Breakout in H2 2026.

DirectionBullish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
INDV ▲ +8.84% at T+60d
LONG call ✓ call won +8.84% · α vs SPY +5.73% · entry $36.78 → $40.03
Entry anchored
Apr 29, 03:59 PM ET
via exchange tick
T+1d
+2.39%
call +2.39% · α +2.17%
$37.66
settled 5mo ago
T+5d
+10.41%
call +10.41% · α +8.69%
$40.61
settled 5mo ago
T+20d
-0.46%
call -0.46% · α -5.43%
$36.61
settled 4mo ago
T+60d
+8.84%
call +8.84% · α +5.73%
$40.03
settled 2mo ago

Price Chart

Loading chart...

Executive Summary

Indivior reported Q1 2026 results with total net revenue of $317M (+19% YoY) and GAAP diluted EPS of $0.69, beating the consensus estimate of $0.64. The company raised its full-year 2026 guidance across all key metrics, including total net revenue to $1.215B-$1.285B and adjusted EBITDA to $620M-$660M (+50% YoY at midpoint). The strong beat and raised guidance are driven by accelerating SUBLOCADE net revenue (+32% YoY) and record quarterly adjusted EBITDA of $164M (+112% YoY).

Key Financial Metrics

EPS
$0.69
est $0.64 · +7.8%
Revenue
$317.0M
est $272.8M · +16.2% · +19.2% YoY
Rating
strong beat
Guidance
$1.215B-$1.285B
raised
Free Cash Flow
-$29.0M
Gross Margin
87.4%

Key Facts

  • Q1 2026 total net revenue of $317M, up 19% YoY from $266M
  • Total SUBLOCADE net revenue of $232M, up 32% YoY from $176M
  • GAAP net income of $89M ($0.69 diluted EPS) vs $47M ($0.38) YoY
  • Non-GAAP net income of $123M ($0.96 diluted EPS) vs $56M ($0.45) YoY
  • Record quarterly adjusted EBITDA of $164M, up 112% YoY from $78M
  • Raised full-year 2026 guidance: net revenue $1.215B-$1.285B (from $1.125B-$1.195B)
  • Raised SUBLOCADE net revenue guidance to $950M-$990M (from $905M-$945M)
  • Raised adjusted EBITDA guidance to $620M-$660M (from $535M-$575M)
  • Repurchased ~4M shares for $125M in Q1; $275M remaining under $400M buyback program
  • Completed $500M convertible senior notes offering; repaid $333M term loan
  • Discontinued internal development of INDV-6001 and INDV-2000 pipeline assets

Financial Impact

Q1 revenue beat consensus by ~$44M (16%); EPS beat by ~$0.05 (7.8%); full-year guidance raised by $90M at midpoint for revenue and $85M for adjusted EBITDA

revenueepsebitdaguidanceshare buyback

Risk Factors

  • Pipeline setbacks with discontinuation of INDV-6001 and INDV-2000 reduce long-term growth optionality
  • SUBLOCADE faces eventual patent cliff starting 2031-2038
  • Operating cash flow was negative $9M in Q1 due to working capital timing; full-year guidance of ~$340M depends on execution
  • Convertible notes add $500M debt; dilution risk if shares convert

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-193925
Document: d40828dex993.htm0001193125-26-193925
Document: d40828dex992.htm0001193125-26-193925
Document: d40828d8k.htm0001193125-26-193925
Document: 0001193125-26-193925-index-headers.html0001193125-26-193925
Document: 0001193125-26-193925-index.html0001193125-26-193925
Document: 0001193125-26-193925.txt0001193125-26-193925
8-K Data (Synthetic)0001193125-26-193925
18 reports for INDV
Performance horizon
100% Hit rate 6 of 6 directional calls best @ T+60▲ +21.73%Apr 24, 2026
Filters
Rows
Reports for INDV — sortable, filterable
TypeNow
Sep 14, 2026
18d ago
EFFECT
NEUTRAL ★ 4/10
$34.47 $35.53▲ +3.08%▲ +2.97%$35.71 (+3.60%)
Aug 28, 2026
4w ago
S-4
NEUTRAL ★ 6/10
$34.93 $34.32▼ −1.75%▼ −1.60%$35.71 (+2.23%)
Aug 3, 2026
8w ago
425 / 8-K
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
425
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
8-K
BULLISH ★ 8/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Aug 3, 2026
8w ago
425 / 8-K
BULLISH ★ 7/10
$37.37 $38.47▲ +2.94%▲ +0.92%$35.71 (−4.44%)
Jul 23, 2026
10w ago
Press Release
NEUTRAL ★ 2/10
$40.51 $40.22▼ −0.72%▼ −1.19%$35.71 (−11.85%)
Jun 12, 2026
16w ago
Insider Cluster
NEUTRAL ★ 4/10
$38.40 $38.32▼ −0.21%▲ +1.17%$35.71 (−7.01%)
May 15, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$36.54 $37.81▲ +3.48%▲ +1.86%$35.71 (−2.27%)
May 4, 2026
21w ago
8-K
NEUTRAL ★ 3/10
$38.98 $38.84▼ −0.36%▼ −3.30%$35.71 (−8.39%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (64h 38m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access